Published in Lupus on January 01, 2001
Sex differences in autoimmune disease from a pathological perspective. Am J Pathol (2008) 1.94
Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum (2008) 1.53
Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol (2012) 1.06
Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J Biomed Biotechnol (2010) 0.92
Interferons in autoimmune and inflammatory diseases: regulation and roles. J Interferon Cytokine Res (2011) 0.91
Emerging roles for the interferon-inducible p200-family proteins in sex bias in systemic lupus erythematosus. J Interferon Cytokine Res (2011) 0.86
Management of pregnancy in systemic lupus erythematosus. Nat Rev Rheumatol (2012) 0.84
Sex hormones and immune dimorphism. ScientificWorldJournal (2014) 0.79
Influence of KIR genes and their HLA ligands in the pathogenesis of leprosy in a hyperendemic population of Rondonópolis, Southern Brazil. BMC Infect Dis (2014) 0.77
Cutaneous warts in patients with lupus erythematosus. Rheumatol Int (2003) 0.75
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum (1996) 6.88
DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol (2000) 4.51
Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61
Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci U S A (1998) 3.35
Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med (2000) 3.07
Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med (1987) 2.71
Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum (2001) 2.68
Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol (2001) 2.61
Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol (1997) 2.59
Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol (2001) 2.49
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol (1999) 2.23
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
Cardiac involvement in systemic lupus erythematosus. Lupus (2005) 2.08
Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum (2000) 2.06
Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus (2002) 2.03
Genomic DNA released by dying cells induces the maturation of APCs. J Immunol (2001) 2.03
An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum (2005) 1.96
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84
Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest (1992) 1.84
A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum (2001) 1.82
Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci U S A (1996) 1.82
Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J Exp Med (1997) 1.73
The histologic spectrum of prepuces from patients with phimosis. Am J Dermatopathol (1988) 1.73
Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun (2011) 1.70
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol (1989) 1.67
Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) (1987) 1.67
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65
Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol (1999) 1.58
Distinct patterns of cytokine secretion characterize new onset synovitis versus chronic rheumatoid arthritis. J Rheumatol (1998) 1.55
Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjögren's syndrome. J Rheumatol (1994) 1.54
A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol (1998) 1.54
Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun (2008) 1.53
Cyclophosphamide for lupus during pregnancy. Lupus (2005) 1.52
Atraumatic osteonecrosis of the humeral head. J Rheumatol (2000) 1.51
Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med (1998) 1.51
Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc Natl Acad Sci U S A (1999) 1.48
Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol (1996) 1.46
Studies of consomic mice bearing the Y chromosome of the BXSB mouse. J Immunol (1985) 1.44
The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med (1987) 1.42
The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis (2007) 1.37
Assessment of systemic lupus erythematosus. Clin Exp Rheumatol (2005) 1.37
Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum (2005) 1.35
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34
Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol (2001) 1.33
Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol (1999) 1.29
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2009) 1.27
Non-tropical sprue. Malignant diseases and mortality rate. Scand J Gastroenterol (1985) 1.27
Autoimmunity and increased c-myb transcription. Science (1984) 1.27
An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol (2008) 1.25
Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J Immunol (1995) 1.24
The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford) (2004) 1.23
Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus (2011) 1.23
Microbial products induce autoimmune disease by an IL-12-dependent pathway. J Immunol (1997) 1.21
Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine (1999) 1.20
Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol (1999) 1.19
CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect Immun (2000) 1.19
Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis Rheum (1996) 1.18
Systemic lupus erythematosus one disease or many? Autoimmun Rev (2011) 1.18
Proliferation of anti-DNA-producing NZB B cells in a non-autoimmune environment. J Immunol (1986) 1.17
International consensus for a definition of disease flare in lupus. Lupus (2010) 1.16
Oncogene expression in autoimmune and normal peripheral blood mononuclear cells. J Exp Med (1986) 1.15
Effect of intravenous insulin infusion on mortality among diabetic patients after myocardial infarction. Br Heart J (1984) 1.14
The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum (2001) 1.14
An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis (2010) 1.12
The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol (1998) 1.12
Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids. Infect Immun (1998) 1.09
Induction of neonatal tolerance by plasmid DNA vaccination of mice. J Clin Invest (1996) 1.08
Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr (1995) 1.08
Peripheral neuropathies in systemic lupus erythematosus: clinical features, disease associations, and immunologic characteristics evaluated over a twenty-five-year study period. Arthritis Rheumatol (2014) 1.08
Sequence analysis and expression of an X-linked, lymphocyte-regulated gene family (XLR). J Exp Med (1987) 1.07
Plasma vasopressin concentrations and effects of vasopressin antiserum on blood pressure in rats with malignant two-kidney Goldblatt hypertension. Circ Res (1978) 1.07
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) (2012) 1.06
Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology (2000) 1.06
SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) (2008) 1.06
NIH conference. Systemic lupus erythematosus. Ann Intern Med (1991) 1.06
Percutaneous vertebroplasty treatment of steroid-induced osteoporotic compression fractures. Arthritis Rheum (1998) 1.05
Studies on Nosema cuniculi found in transplantable ascites tumours with a survey of microsporidiosis in mammals. Acta Pathol Microbiol Scand Suppl (1969) 1.04
Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension. Am J Physiol (1977) 1.04
Estimating renal function in lupus nephritis: comparison of the Modification of Diet in Renal Disease and Cockcroft Gault equations. Lupus (2007) 1.04
Theoretical and experimental approaches to generalized autoimmunity. Immunol Rev (1990) 1.03
Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum (1999) 1.03
Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest (1998) 1.03
Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four women. Arthritis Rheum (1987) 1.03
Heterogeneous expression and coordinate regulation of endogenous retroviral sequences in human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses (1992) 1.02
Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum (2005) 1.02
Is vasopressin involved in the pathogenesis of malignant desoxycorticosterone hypertension in rats? Lancet (1976) 1.02
Pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am (1988) 1.02
CpG motifs of DNA vaccines induce the expression of chemokines and MHC class II molecules on myocytes. Eur J Immunol (2001) 1.01
Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus (2000) 1.01
Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum (2008) 1.01
Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. Lupus (2011) 1.00
T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity. J Clin Immunol (1994) 0.99
Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. J Rheumatol (1996) 0.99